Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474850 | 1.00 | NPY5R (0.40) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL474721 | 1.00 | NPY5R (0.40) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL17185334 | 0.89 | — | — | |
| SCHEMBL11842283 | 0.83 | NOS3 (0.45) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL2176405 | 0.83 | DPP4 (0.43) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL6335314 | 0.83 | NOS3 (0.45) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL23917218 | 0.81 | NOS3 (0.43) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL20858617 | 0.81 | NOS3 (0.43) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL22889 | 0.81 | NOS3 (0.43) | NPY5RBRD4BRD2NOS3NOS1 | |
| SCHEMBL22859782 | 0.80 | NPY5R (0.38) | NPY5RBRD4BRD2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049475-B1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998999-B2 | Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-16 | — | — | US | disclosed |
| CN-101432262-B | Cyclohexyl-substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI | 2011-06-01 | — | — | CN | disclosed |
| US-20090239911-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-09-24 | — | — | US | disclosed |
| CN-101432262-A | Cyclohexyl-substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI (US) | 2009-05-13 | — | — | CN | disclosed |
| EP-2049475-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007127704-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239911-A1 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | NPY5R 706/4885BRD4 2484/4885BRD2 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.